Pembrolizumab-Epacadostat Combination to Treat Muscle-invasive Bladder UrotheLIAl canceR: PECULIAR Study
Status:
Withdrawn
Trial end date:
2019-05-22
Target enrollment:
Participant gender:
Summary
An open label, monocenter, single-arm, phase 2 study of neoadjuvant pembrolizumab and
epacadostat, preceding radical cystectomy, for patients with muscle-invasive bladder cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano